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A B S T R A C T
The uncovering of a positive association between inflammatory cytokine levels – Interkleukin-6 (IL-6) in par-
ticular – and the experiencing of depressive and anxiety symptoms is one of the most promising and en-
thusiastically-discussed finding in recent years. Despite considerable ambiguity in the directionality and un-
derpinnings of this association, anti-inflammatory drugs are already being tested on mental health patients who
present no physical symptoms of inflammation, risking potential adverse side effects. Researchers have thus
urgently called for more rigorous empirical elucidations of this association. Based on a large, longitudinal,
nationally representative sample of middle-aged adults in the United States (N= 1255), IL-6 was observed to be
significantly associated with one's present experiencing of depressive and anxiety symptoms. However, IL-6 was
predictive of only prospective depressive (not anxiety) symptoms measured six years later, and only when
baseline number of symptoms was not accounted for. Further, evidence for IL-6’s postulated role as being either
a biological cause itself (augmenting HPA stress reactivity) or a biological consequence of a psychological cause
(psychological stress) for depression and anxiety was not found. These findings underscore the imperativeness of
more rigorous studies to be conducted in this area, and caution practitioners against the premature consideration
of IL-6 levels in clinical practice.
1. Introduction
The potential role of inflammation in the pathogenesis of mental
disorders has garnered substantial interest in recent years from both
researchers and practitioners alike. In particular, recent studies have
demonstrated a rather consistent correlation between elevated blood-
circulating inflammatory cytokines and the presence of depressive and
anxiety symptoms (Dantzer, 2012; Dregan et al., 2019; Salim et al.,
2012; Yang et al., 2016; Zunszain et al., 2013). However, even though
the directionality and underpinnings of this association remain unclear,
popular media outlets have begun reporting that inflammatory cyto-
kines may be used as a biological marker of depression and anxiety
disorder and that anti-inflammatory drugs may be used in treating such
disorders (Abbott, 2018; Azab, 2018; DiSalvo, 2019). Alarmingly, re-
search clinicians have started to administer anti-inflammatory drugs,
which carry risks of adverse side effects, to treat depression and anxiety
disorder even when patients present no overt, physical symptoms of
inflammation; such attempts have yielded equivocal results thus far
(Eyre et al., 2015; Köhler et al., 2014; Köhler-Forsberg et al., 2019;
Miller and Raison, 2015). Concerned researchers have thus warned
against such premature consideration of inflammatory cytokines in
clinical practice and called for more rigorous empirical studies to shed
more light on this association (Miller and Raison, 2015). Heeding such
prudent calls, this paper aims to provide a closer inspection of this
association with the use of a large, longitudinal, nationally re-
presentative sample.
Inflammation is broadly defined as an immune response involving
the induction of intracellular and extracellular inflammatory cytokines
that mediate cellular damage; the primary target of such a response is
typically an invading pathogen, but it can also erroneously target one's
own body part as in the case of autoimmunity (Lindholt and Shi, 2006).
Chronic autoimmune inflammation plays a central role in the etiology
of chronic inflammatory diseases, such as asthma and arthritis, where
elevated levels of inflammatory cytokines cause prolonged tissue da-
mage at the affected site (Ballantyne et al., 2007; Furuzawa-
Carballeda et al., 2007; Trentham et al., 1977). While mental illnesses
are not traditionally deemed to be inflammatory diseases, a rather
consistent positive correlation observed between blood-circulating in-
flammatory cytokine levels and the experiencing of depressive and
anxiety symptoms has led researchers to propound that inflammation
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could play an important role in the pathogenesis of depression and
anxiety disorder (Salim et al., 2012; Zunszain et al., 2013).
In particular, the inflammatory cytokine interleukin-6 (IL-6) has
been consistently observed to be positively associated with increased
depressive (Alesci et al., 2005; Yoshimura et al., 2009) and anxiety
symptoms experienced (Murphy et al., 2015; O'Donovan et al., 2010).
However, researchers are still unclear as to why and how IL-6 is related
to the precipitation of such symptoms and the development of depres-
sion and anxiety disorder. Some researchers propose that IL-6 is directly
involved in the etiology of these disorders, whereby inflammatory re-
sponses associated with elevated IL-6 levels trigger increased oxidative
stress that influences the brain's functioning and signaling patterns
(Krishnadas and Cavanagh, 2012; Lindqvist et al., 2017; Maes, 2008;
Salim et al., 2011; Szuster-Ciesielska et al., 2008). Notably, it is posited
that this results in the augmentation of the Hypothalamus-Pituitary-
Adrenal (HPA) axis, which elevates an individual's stress reactivity and
precipitate depressive and anxiety symptoms over time (Maes et al.,
1993; Soygur et al., 2007). Others propound that IL-6 is a biological
consequence or byproduct of increased psychological stress – the pri-
mary cause of these disorders instead; in this view, IL-6 serves merely as
an early indicator of depression and anxiety disorder as opposed to
being a cause itself (Butterweck et al., 2003; Lutgendorf et al., 1999;
Maes et al., 1998). The former suggests both a predictive and causative
role of IL-6 whereas the latter suggests only a predictive role of IL-6.
Adding to the ambiguity, most of these studies conducted were
correlational and cross-sectional in nature (Dentino et al., 1999;
Lutgendorf et al., 1999; Murphy et al., 2015; O'Donovan et al., 2010).
This means that the direction of causality cannot be ascertained with
confidence to begin with. When both IL-6 and symptoms of depression
and anxiety disorder are measured simultaneously at a single time
point, it cannot be ruled out if the mental toll from experiencing these
symptoms may have resulted in an elevation of IL-6 levels instead, or if
an unaccounted third variable may have been driving both the pre-
cipitation of depressive and anxiety symptoms as well as a rise in IL-6
levels (Dantzer, 2012). Even among the handful of studies that have
adopted a longitudinal design, none has ever endeavored to examine IL-
6 in relation to both depressive and anxiety symptoms simultaneously
or to directly examine the underpinnings of IL-6’s association with the
precipitation of these symptoms (Gimeno et al., 2009; Khandaker et al.,
2014; Valkanova et al., 2013). This severely precludes us from ob-
taining a holistic and nuanced understanding of the relationship be-
tween IL-6 and these implicated mental disorders that often are co-
morbid (Gorman, 1996; Hirschfield, 2001).
Addressing these gaps, this present study employs a longitudinal
study design to examine IL-6’s proposed role as a predictor of the
precipitation of depressive and anxiety symptoms. Additionally, in an
attempt to disambiguate current competing postulations of IL-6’s role as
either being a biological cause itself or a biological consequence/by-
product of a psychological cause, both cortisol stress reactivity as well
as psychological stress levels will be directly assessed in this study. If
stress reactivity is found to significantly mediate a relationship between
IL-6 and prospective depressive and anxiety symptoms experienced, it
would lend support to the notion that IL-6 may be a biological cause of
depressive and anxiety symptom precipitation via augmentation of HPA
axis. On the other hand, if psychological stress level is found to be a
significant predictor of both IL-6 levels and prospective depressive and
anxiety symptoms experienced, it would lend support to the notion that
IL-6 might be a biological consequence of psychological stress rather
than a direct cause of depressive and anxiety symptom precipitation.
2. Methods
2.1. Subjects
Participants consisted of 1255 middle-aged adults who completed
the Midlife in the United States II: Biomarker Project, which was
conducted between 2004 and 2009 (Ryff et al., 2019a). The sample is a
subset of a large-scale longitudinal project from the original MIDUS 1
survey that began in 1995, with 7108 noninstitutionalized adults re-
cruited through random digit sampling from 48 contiguous states. In
the Biomarker Project, participants were invited for an overnight hos-
pital stay in one of three general clinical research centers in the United
States (University of California, Los Angeles; Georgetown University;
and University of Wisconsin-Madison). During which, participants un-
derwent a physical exam that included the collection of a fasting blood
sample before breakfast on the second day of their hospital stay. This
will be referred to as Time 1 in this paper. A follow-up survey was
subsequently, successfully conducted on 945 of these participants be-
tween 2013 and 2015 (Ryff et al., 2019b). This will be referred to as
Time 2 in this paper. The average number of years elapsed between
Time 1 and Time 2 is six years. Those who did not respond in MIDUS 3
as well as 2 participants with mismatching MIDUS family identification
number between the waves were excluded from analyses, leaving for a
final sample size of 943.
These studies were approved by the University of Wisconsin-
Madison, Health Sciences Institutional Review Board. Informed consent
was obtained for all participants. The data that support the findings of
this study, along with detailed descriptions of the study protocol, are
openly available in https://www.icpsr.umich.edu/icpsrweb/NACDA/
studies/29282 (MIDUS 2 Biomarker Project) and https://www.icpsr.
umich.edu/icpsrweb/NACDA/studies/36346 (MIDUS 3). All relevant
descriptive statistics are summarized in Table 1.
2.2. Measures and procedures
2.2.1. Depressive and anxiety symptoms
Depressive symptoms experienced was measured using the World
Health Organization composite international diagnostic interview -
short form version (CIDI-SF) where participants responded, on a yes-or-
no basis, to 7 questions on whether they had experienced thoughts or
feelings related to depression during the past twelve months, such as
losing of appetite, feeling more tired and low on energy than usual, and
thinking a lot about death. All “yes” responses to these questions were
then summed. Anxiety symptoms experienced was measured in the
same way based on 10 questions, such as whether they were restless
due to their worries or whether they had trouble remembering things
due to their worries. These questions were constructed in accordance to
the definitions and criteria specified in the third edition of the American
Psychiatric Association's Diagnostic and Statistical Manual of Mental
Disorders as well as the 10th version of the Composite International
Diagnostic Interview (Kessler et al., 1999).
2.2.2. Interleukin-6
To assess IL-6 levels, fasting blood samples were collected from each
participant and stored in a −60 °C to −80 °C freezer, which were
subsequently shipped in a dry ice container to the MIDUS Biocore la-
boratory. Serum-level IL-6 was measured using the Quantikine® high-
sensitivity enzyme-linked immunosorbent assay (ELISA) kit #HS600B
(R&D Systems, Minneapolis, MN). The assay range and reference range
were 0.156–10 pg/mL and 0.45–9.96 pg/mL respectively. The labora-
tory inter-assay coefficient of variance was 12.31% and the intra-assay
coefficient of variance was 3.25%, which were within an established
acceptable range (Desilva et al., 2003).
2.2.3. Stress reactivity
Consistent with past studies, stress reactivity was assessed by sub-
tracting baseline, resting salivary cortisol levels from salivary cortisol
levels after engaging in stressful cognitive tasks (Neupert et al., 2006).
An established stress reactivity protocol was adopted from (Fuller-
Rowell et al., 2013), whereby participants were first allowed to rest for
11 min before a sample of their saliva was obtained (baseline cortisol
level). Next, participants engaged in a stressful cognitive task for 6 min,
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followed by 6 min of rest. Participants then engaged in another stressful
cognitive task for 6 min followed by another 6 min of rest, before a
sample of their saliva was collected again (post-stress cortisol level).
The stressful cognitive tasks administered were the Morgan And Turner
Hewitt (MATH) arithmetic task and the Stroop Color-Word task (order
of presentation counterbalanced). A detailed description of the tasks is
available at http://www.midus.wisc.edu/midus2/.
Saliva samples were collected via cottons swabs from Salivette®.
Participants were instructed to place the cotton swab in their mouth,
chew it until saturated with saliva, then put it back in the provided tube
and recap it. These samples were stored in a −80 °F freezer and sent to
the Technical University of Dresden for cortisol assay by im-
munochemical luminescence at the end of the session. Two saliva
samples were collected from each participant at each phase (baseline
and post-cognitive task) and the average between each set of two were
taken. One data was dropped from analyses as it was an extreme outlier
(more than 3 standard deviations from the mean) that was possibly a
result of measurement errors. It had a mean baseline salivary cortisol
level of 1889.311 nmol/L and a mean post-cognitive task salivary
cortisol level of 480.448 nmol/L, both of which are more than double
the normal human range of cortisol levels (Laudat et al., 1988;
Ljubijankić et al., 2008). All other data were within expected normal
ranges.
2.2.4. Psychological stress
Level of psychological stress experienced was measured using the
established 10-item Perceived Stress Scale (PSS; Cohen, 1988; Cohen,
Kamarck, & Mermelstein, 1983). On a scale of 1 being never to 5 being
very often, participants were tasked to indicate how often they experi-
enced certain stress-related thoughts or feelings, such as “felt difficul-
ties were piling up so high that you couldn't overcome them” or “found
that you could not cope with all the things that you had to do”. Past
studies have rigorously evaluated the scale and deemed it to be a valid
and reliable measure of psychological stress experienced (Lee, 2012;
Roberti et al., 2006).
2.2.5. Covariates
A set of variables were also controlled for due to their potential
confounding effects. For demographics, age, sex, marital status, and
socioeconomic status (education level and income) were accounted for.
Consistent with past studies (Braveman, 2001; Hartanto et al., 2019),
income was stratified into quartiles and operationalized as a continuous
variable (Q1: less than $16,000; Q2: $17,000–$34,000; Q3:
$34,750–$61,250; Q4: more than $62,500). Personality trait was also
accounted for due to their established association with depressive and
anxiety symptoms (Bolger and Eckenrode, 1991; Lara et al., 1997;
Matsudaira and Kitamura, 2006). Personality was assessed under the
Big Five framework using participants’ responses to a 25-item adjective-
based measure, indicating how much each adjective described them-
selves on a scale of 1 being not at all to 4 being a lot. The scale was
developed for use in MIDUS through a combination of existing per-
sonality inventories and has been validated in a study of 1000 partici-
pants (Lachman and Weaver, 1997).
Participants’ physical health status and medication use were also
accounted for. Based on the suggestions of past studies (Dregan et al.,
2019), BMI, systolic blood pressure, and number of physical co-
morbidities (e.g., chronic heart disease, cancer, arthritis) were assessed.
Additionally, use of medications that may impact either IL-6 levels or
depressive/anxiety symptoms experienced were accounted for; this in-
cluded use of oral anti-inflammatory medications, sedatives, tranquili-
zers, stimulants, and anti-depressants.
3. Results
All analyses were conducted using Poisson regression, because both
dependent variables are count data (Coxe et al., 2009; Hutchinson and
Holtman, 2005). The first set of analyses tested whether IL-6 was as-
sociated with number of depressive and anxiety symptoms experienced
Table 1
Descriptive statistics.
Time 1 Time 2
n M (SD) Range n M (SD) Range
Demographic
Age 943 57.18 (10.95) 35–86 943 63.46 (11.08) 43–92
Sex (% of male) 943 44.4%
Marital Status (% of married) 942 73.20% 943 66.80%
Citizenship (% US citizen) 943 99.7%
Education Level 941 7.80 (2.45) 1–12 943 7.80 (2.43) 1–12
Income 907 2.53 (1.12) 1–4 857 2.86 (1.10) 1–4
Personality
Openness to Experience 936 2.98 (0.52) 1.00–4.00 893 2.95 (0.54) 1.43–4.00
Conscientiousness 940 3.42 (0.44) 1.80–4.00 893 3.42 (0.46) 1.60–4.00
Extraversion 940 3.14 (0.57) 1.20–4.00 893 3.12 (0.56) 1.20–4.00
Agreeableness 940 3.44 (0.50) 1.20–4.00 893 3.43 (0.51) 2.00–4.00
Neuroticism 940 2.03 (0.63) 1.00–4.00 893 2.02 (0.62) 1.00–4.00
Physical Health Status and Medication Use
Body Mass Index (BMI) 942 29.05 (5.91) 16.49–60.39 871 28.19 (5.96) 16.14–56.82
Blood Pressure (Systolic, mmHg) 942 130.64 (17.64) 83–191 –
Number of Physical Comorbidities 943 3.89 (2.87) 0–20 894 3.21 (3.03) 0–20
Use of Sedatives (% of yes) 941 3.3% 895 3.0%
User of Tranquilizers (% of yes) 941 2.7% 895 2.0%
Use of Stimulants (% of yes) 940 1.0% 893 0.2%
Use of Anti-Depressants (% of yes) 940 1.5% 894 1.6%
Use of Oral Anti-Inflammatory Drug (% of yes) 864 45.8%
Predictor Variables
Serum Interleukin-6 (IL-6) 934 2.57 (2.34) 0.16–21.68
Psychological Stress 941 21.42 (6.11) 10–48
Stress Reactivity 889 1.35 (7.82) −55.14–40.25
Criterion Variables
Number of Depressive Symptoms 943 0.65 (1.78) 0–7 943 0.61 (1.74) 0–7
Number of Anxiety Symptoms 943 0.11 (0.81) 0–10 943 0.12 (0.85) 0–10
Note. Education was assessed on a scale of 1 (No school) to 12 (Ph.D, ED. D, MD, LLB, LLD, JD, or other professional degree).
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in Time 1. Number of depressive and anxiety symptoms experienced in
Time 1 were separately regressed on IL-6 levels. IL-6 was found to be
significantly, positively associated with both depressive symptoms ex-
perienced in Time 1, B = 0.07, SE = 0.01, 95% CI = [.05, 0.10],
p < .001, and anxiety symptoms experienced in Time 1, B = 0.08,
SE= = 0.03, 95% CI = [.02, 0.14], p= .006. As seen in Tables 2 and
3, these results held even when demographics and personality variables
(Model 2) as well as physical health and medication use status (Model
3) were controlled; with the exception of the relationship between IL-6
and anxiety symptoms experienced in Time 1, which was rendered non-
significant after controlling for physical health and medication use
status.
The second set of analyses examined whether IL-6 levels measured
in Time 1 significantly predicted number of depressive and anxiety
symptoms experienced in Time 2. Number of depressive and anxiety
symptoms experienced in Time 2 were separately regressed on IL-6
levels. IL-6 significantly predicted increased depressive symptoms ex-
perience in Time 2, B = 0.05, SE = 0.01, 95% CI = [.03, 0.08],
p < .001, but was unassociated with anxiety symptoms experienced in
Time 2, B = 0.06, SE = 0.03, 95% CI = [−0.01, 0.12], p = .082.
Critically, however, as seen in Tables 4 and 5, IL-6 was not a significant
predictor of depressive or anxiety symptoms experienced in Time 2
when number of symptoms experienced in Time 1 (i.e., baseline) was
controlled (Model 2). These results remained non-significant after ad-
ditionally controlling for demographics and personality variables
(Model 3) as well as physical health and medication use status (Model
4).
The third set of analyses examined stress reactivity as a potential
mediator between IL-6 levels at Time 1 and number of depressive and
anxiety symptoms experienced in Time 2. A Poisson-based mediation
analysis was conducted using Mplus with IL-6 specified as the predictor,
stress reactivity as the mediator, and number of depressive symptoms
experienced in Time 2 as the outcome variable. As shown in Table 6, IL-
6 was found to be significantly, negatively associated with stress re-
activity, B=−0.29, SE= 0.11, 95% CI = [−0.51, −0.07], p= .010,
but stress reactivity was not, in turn, associated with number of de-
pressive symptoms in Time 2, B = −0.01, SE = 0.01, 95%
CI = [−0.02, 0.01], p= .331. Expectedly, this indirect path was found
to be non-significant, B = 0.002, SE = 0.002, 95% CI = [−0.002,
0.01], p= .363, and remained so after number of depressive symptoms
experienced in Time 1, B = 0.001, SE = 0.002, 95% CI = [−0.004,
0.01], p= .780, demographics and personality variables, B=−0.002,
SE = 0.002, 95% CI = [−0.01, 0.002], p = .346, and physical health
and medication use status, B = −0.004, SE = 0.003, 95%
CI = [−0.01, 0.002], p = .197, were additionally controlled for.
A separate analysis was then conducted with number of anxiety
symptoms experienced in Time 2 specified as the outcome variable
instead. As shown in Table 7, IL-6 was found to be significantly, ne-
gatively associated with stress reactivity, B = −0.31, SE = 0.11, 95%
CI = [−0.53, −0.09], p = .006, and stress reactivity, in turn, sig-
nificantly predicted decreased number of anxiety symptoms experi-
enced in Time 2, B = −0.07, SE = 0.01, 95% CI = [−0.08, −0.05],
p < .001. This indirect path was found to be statistically significant,
B= 0.02, SE= 0.01, 95% CI = [.01, 0.04], p= .010, and remained so
even after controlling for number of anxiety symptoms experienced in
Time 1, B = 0.02, SE = 0.01, 95% CI = [.001, 0.03], p = .034. This
indirect path, however, was rendered non-significant after demo-
graphics and personality variables, B = 0.01, SE = 0.01, 95%
CI = [−0.01, 0.02], p= .322, and physical health and medication use
status, B= 0.02, SE= 0.01, 95% CI = [−0.001, 0.04], p= .059, were
Table 2
Predicting number of depressive symptoms experienced in Time 1.
Model 1 Model 2 Model 3
B (SE) B (SE) B (SE)
Predictor
Serum Interleukin-6 (IL-6) 0.07
(0.01)⁎⁎⁎


















Income 0.01 (0.04) 0.12 (0.04)⁎⁎
Openness to experience 0.39 (0.10)⁎⁎⁎ 0.27 (0.11)*





Agreeableness 0.29 (0.10)⁎⁎ 0.30 (0.11)⁎⁎
Neuroticism 1.05 (0.07)⁎⁎⁎ 0.93 (0.08)⁎⁎⁎
Body Mass Index 0.003 (0.007)




Use of Sedatives −0.61 (0.24)*
User of Tranquilizers 0.18 (0.21)
Use of Stimulants 1.20 (0.33)⁎⁎⁎
Use of Anti-Depressants 0.32 (0.24)
Use of Oral Anti-Inflammatory
Drug
−0.03 (0.09)
Note: Sex was dummy coded with “female” as reference. Marital status was
dummy coded with “currently unmarried” as reference. Use of medications was
dummy coded with “no” as reference.
⁎ p < .05.
⁎⁎ p < .01.
⁎⁎⁎ p < .001.
Table 3
Predicting number of anxiety symptoms experienced in Time 1.
Model 1 Model 2 Model 3
B (SE) B (SE) B (SE)
Predictor
Interleukin-6 (IL-6) Level 0.08
(0.03)⁎⁎





Sex 0.10 (0.31) 0.58 (0.37)





Income −0.17 (0.13) 0.01 (0.17)
Openness to experience 0.41 (0.30) 0.44 (0.42)




Agreeableness 0.95 (0.30)⁎⁎ 1.18 (0.39)*
Neuroticism 2.82 (0.24)⁎⁎⁎ 2.89 (0.30)⁎⁎⁎
Body Mass Index −0.01 (0.03)




Use of Sedatives −1.56 (1.06)
User of Tranquilizers −0.97 (0.76)
Use of Stimulants −7.93
(<0.01)
Use of Anti-Depressants 1.65 (0.65)*
Use of Oral Anti-Inflammatory
Drug
−0.18 (0.36)
Note: Sex was dummy coded with “female” as reference. Marital status was
dummy coded with “currently unmarried” as reference. Use of medications was
dummy coded with “no” as reference.
⁎ p < .05.
⁎⁎ p < .01.
⁎⁎⁎ p < .001.
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additionally controlled for.
The final set of analyses examined psychological stress as a si-
multaneous predictor of both IL-6 levels in Time 1 and number of de-
pressive and anxiety symptoms experienced in Time 2. A Poisson-based
path analysis was conducted using Mplus, with psychological stress
specified as a predictor of both IL-6 levels at Time 1 and number of
depressive symptoms experienced in Time 2. Psychological stress was
not found to be significantly associated with IL-6 levels, B = 0.001,
SE = 0.01, 95% CI = [−0.02, 0.03], p = .938, even though psycho-
logical stress levels significantly predicted increased number of de-
pressive symptoms experienced in Time 2, B= 0 0.11, SE= 0.01, 95%
CI = [.10, 0.13], p< .001. These results held even after controlling for
Table 4
Predicting number of depressive symptoms experienced in Time 2.
Model 1 Model 2 Model 3 Model 4
B (SE) B (SE) B (SE) B (SE)
Predictor
Serum Interleukin-6 (IL-6) 0.05 (0.01)⁎⁎⁎ 0.02 (0.02) 0.02 (0.02) 0.001 (0.02)
Covariates
Depressive Symptoms (Time 1) 0.32 (0.01)⁎⁎⁎ 0.24 (0.02)⁎⁎⁎ 0.20 (0.02)⁎⁎⁎
Age −0.03 (0.01)⁎⁎⁎ −0.03 (0.01)⁎⁎⁎
Sex −0.11 (0.11) −0.09 (0.11)
Marital status −0.05 (0.10) −0.05 (0.10)
Education Level −0.04 (0.02)* −0.04 (0.02)
Income −0.11 (0.04)* −0.07 (0.05)
Openness to experience 0.21 (0.11)* 0.20 (0.11)
Conscientiousness −0.16 (0.11) −0.15 (0.11)
Extraversion −0.22 (0.10)* −0.26 (0.11)*
Agreeableness 0.16 (0.11) 0.11 (0.12)
Neuroticism 0.20 (0.08)⁎⁎ 0.15 (0.09)
Body Mass Index 0.02 (0.01)*
Blood Pressure −0.01 (0.003)*
Number of Physical Comorbidities 0.06 (0.01)⁎⁎⁎
Use of Sedatives 0.10 (0.22)
User of Tranquilizers 0.65 (0.20)⁎⁎
Use of Stimulants 0.82 (0.32)*
Use of Anti-Depressants −0.55 (0.30)
Use of Oral Anti-Inflammatory Drug 0.29 (0.10)⁎⁎
Note: Sex was dummy coded with “female” as reference. Marital status was dummy coded with “currently unmarried” as reference. Use of medications was dummy
coded with “no” as reference.
⁎ p < .05.
⁎⁎ p < .01.
⁎⁎⁎ p < .001.
Table 5
Predicting number of anxiety symptoms experienced in Time 2.
Model 1 Model 2 Model 3 Model 4
B (SE) B (SE) B (SE) B (SE)
Predictor
Serum Interleukin-6 (IL-6) 0.06 (0.03) −0.08 (0.05) −0.06 (0.05) −0.07 (0.06)
Covariates
Anxiety Symptoms (Time 1) 0.57 (0.03)⁎⁎⁎ 0.26 (0.05)⁎⁎⁎ 0.19 (0.06)⁎⁎
Age −0.01 (0.01) −0.02 (0.06)
Sex −0.54 (0.33) −0.44 (0.35)
Marital status −0.35 (0.24) −0.43 (0.29)
Education Level −0.16 (0.06)⁎⁎ −0.11 (0.07)
Income −0.11 (0.13) 0.01 (0.14)
Openness to experience 0.24 (0.28) 0.09 (0.33)
Conscientiousness −1.23 (0.27)⁎⁎⁎ −0.93 (0.32)⁎⁎
Extraversion −0.41 (0.28) −0.24 (0.33)
Agreeableness 1.28 (0.34)⁎⁎⁎ 1.40 (0.42)⁎⁎
Neuroticism 0.89 (0.21)⁎⁎⁎ 1.05 (0.25)⁎⁎⁎
Body Mass Index 0.05 (0.02)*
Blood Pressure −0.003 (0.01)
Number of Physical Comorbidities 0.11 (0.04)⁎⁎
Use of Sedatives 1.10 (0.48)*
User of Tranquilizers −0.52 (0.47)
Use of Stimulants 1.83 (0.73)*
Use of Anti-Depressants 1.27 (0.51)*
Use of Oral Anti-Inflammatory Drug 0.61 (0.29)*
Note: Sex was dummy coded with “female” as reference. Marital status was dummy coded with “currently unmarried” as reference. Use of medications was dummy
coded with “no” as reference.
⁎ p < .05.
⁎⁎ p < .01.
⁎⁎⁎ p < .001.
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number of depressive symptoms experienced in Time 1, demographics
and personality variables, and physical health and medication use
status.
A separate analysis was then conducted with number of anxiety
symptoms experienced in Time 2 specified as the outcome variable
instead. Psychological stress was not found to be significantly asso-
ciated with IL-6 levels, B = 0 0.001, SE = 0.01, 95% CI = [−0.02,
0.03], p = .938, even though psychological stress levels significantly
predicted increased number of anxiety symptoms experienced in Time
2, B=0 0.16, SE= 0.01, 95% CI = [.14, 0.18], p< .001. These results
held even after controlling for number of anxiety symptoms experi-
enced in Time 1, demographics and personality variables, and physical
health and medication use status.
4. Discussion
Based on a large, nationally representative sample of middle-aged
adults in the United States, blood serum interkeukin-6 (IL-6) level was
found to be significantly, positively associated with one's present
number of depressive and anxiety symptoms experienced (i.e., mea-
sured at Time 1). This is consistent with the findings of past correla-
tional, cross-sectional studies that make up the bulk of the current lit-
erature in this area of research (Dentino et al., 1999; Lutgendorf et al.,
1999; Murphy et al., 2015; O'Donovan et al., 2010). It should, however,
be noted that the association between IL-6 and number of anxiety
symptoms experienced was rendered non-significant when physical
health and medication use status were controlled, suggesting for the
possibility that one's physical health and medication use status may
serve as a third-variable responsible for the simultaneous fluctuations in
levels of IL-6 and anxiety symptoms experienced.
Critically, IL-6 was not found to be a significant predictor of number
of depressive or anxiety symptoms measured at Time 2 when number of
symptoms assessed at Time 1 (i.e., baseline) was controlled; though,
without controlling for baseline, IL-6 was a significant predictor of
number of depressive symptoms experienced in Time 2 (but not number
of anxiety symptoms). However, given that this association was ren-
dered non-significant after controlling for baseline, it can be said that
IL-6 provides no incremental predictive validity over one's current
number of depressive symptoms experienced, such that it rendered a
non-significant predictor when the latter is controlled for. This suggests
that the observed association between IL-6 and one's prospective
number of depressive symptoms is likely driven by the former's sheer
association with one's current number of depressive symptoms rather
than it being a possible cause of prospective depressive symptoms ex-
perienced itself. As demonstrated in past studies, early depression levels
in-particular are significantly predictive of future depression levels
(e.g., Chassin et al., 1999; Nolen-Hoeksema et al., 1992).
Taken together, these findings suggest that IL-6 levels may simply
be fluctuating with one's current experiencing of depressive and anxiety
symptoms and may not be directly involved in the pathogenesis and
development of depression and anxiety disorder; though IL-6 may still
potentially be used as a predictor of future depression levels due to its
sheer association with one's current depression levels and the estab-
lished predictive validity of the latter.
Further corroborating the proposition that IL-6 may not play a
causative role in the pathogenesis and development of depression and
anxiety disorder, evidence for IL-6 serving as either a direct biological
base for the precipitation of depressive and anxiety symptoms (via
augmenting HPA stress reactivity) or a biological consequence/by-
product of a psychological base (psychological stress experienced) was
not found. Specifically, mediation analyses did not support the ex-
istence of an indirect relationship between IL-6 and number of de-
pressive and anxiety symptoms experienced in Time 2 via stress re-
activity levels (with one exception discussed below). Separately, path
analyses revealed that while psychological stress levels experienced in
Time 1 significantly predicted increased depressive and anxiety symp-
toms experienced in Time 2, psychological stress levels were not sig-
nificantly associated with IL-6 levels.
Interestingly, IL-6 was observed to exert a significant, positive in-
direct effect on anxiety symptoms experienced in Time 2 via stress re-
activity in an unexpected manner when demographics and personality
variables as well as physical health and medication use were not con-
trolled for. Specifically, it was observed that higher levels of IL-6 was
associated with lower levels of stress reactivity, which, in turn, was
negatively associated with anxiety symptoms experienced in Time 2.
This goes against our current understanding that stress reactivity would
precipitate anxiety symptoms (e.g., Dorn et al., 2003), and that IL-6
may precipitate such symptoms by increasing stress reactivity. Further
empirical studies are needed to validate and explicate this unexpected
finding. It should, however, be noted that these associations were
rendered non-significant when covariates such as demographics and
personality variables as well as physical health and medication use
were controlled for, indicating that it is highly likely that this finding
may have been confounded.
Collectively, results of this study suggest that IL-6 is only robustly
related to one's current experiencing of depressive and anxiety symp-
toms. While some evidence supporting the predictive validity of IL-6 for
prospective depressive symptoms was obtained, evidence of its pre-
dictive validity for prospective anxiety symptoms was not found.
Furthermore, evidence for IL-6 as being either a direct biological cause
(augmenting HPA stress reactivity) or a biological consequence of a
psychological cause (psychological stress) was not found. It is plausible
that IL-6 may instead be a consequence or byproduct of depression and
anxiety, such that its level fluctuates with an individual's concurrent
depressive and anxiety symptoms experienced, but in itself does not
substantively influence the trajectory or development of depression and
anxiety. Overall, these findings cast reasonable doubt with regard to
our current understanding of IL-6’s role in the pathogenesis of depres-
sion and anxiety disorder and caution practitioners against the pre-
mature consideration of IL-6 in clinical practice.
4.1. Limitations and future directions
Although the current study employed a longitudinal study design
and a large nationally representative sample which enabled us to rule
out a number of confounding factors, some limitations exist. Firstly, the
current study was conducted solely in the U.S., which potentially limits
the generalizability of these findings. Thus, it is important that future
studies attempt to replicate these findings with samples from other
countries to assess the generalizability of these findings. Secondly, IL-6,
psychological stress, and stress reactivity were only measured in Time
1. While this does not compromise the main purpose and analyses of
Table 6
Stress reactivity as a mediator between IL-6 and depressive symptoms (Time 2).
Model B SE (B) 95% CI p
Outcome: Stress Reactivity
IL-6 −0.29 0.11 [−0.51, −0.07] .010
Outcome: Depressive Symptoms (Time 2)
IL-6 0.05 0.01 [.02, 0.08] <.001
Stress Reactivity −0.01 0.01 [−0.02, 0.01] .331
Table 7
Stress reactivity as a mediator between il-6 and anxiety symptoms (Time 2).
Model B SE (B) 95% CI p
Outcome: Stress Reactivity
IL-6 −0.31 0.11 [−0.53, −0.09] .006
Outcome: Anxiety Symptoms (Time 2)
IL-6 0.05 0.03 [−0.02, 0.11] .166
Stress Reactivity −0.07 0.01 [−0.08, −0.05] <.001
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this study, as these variables are proposed to be predictive of pro-
spective depressive and anxiety symptoms, it precludes us from making
any assessment with regards to changes in these variables between the
two time points and how they may concurrently relate to the number of
depressive and anxiety symptoms at Time 2. Such an assessment would
have provided additional empirical information to evaluate the possi-
bility that IL-6 may instead be a consequence or byproduct of depres-
sion and anxiety, as postulated in the discussion section. As this lim-
itation stem primarily from resource constraints, others with greater
means are encouraged to measure these implicated variables at two
time points to assess the validity of this postulation.
4.2. Conclusion
The present study replicates past findings on the positive relation-
ship between IL-6 and concurrent depressive and anxiety symptoms
experienced. However, evidence to support a causative role of IL-6 in
the precipitation of depressive and anxiety symptoms was not found.
On the other hand, evidence for a predictive role of IL-6 was only
limited to prospective depressive symptoms, and only when baseline
number of symptoms is not accounted for. These findings underscore
the imperativeness of more rigorous studies to be conducted in this
area, and caution practitioners against the premature consideration of
IL-6 levels in clinical practice.
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